Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

70.99 -2.94 (-3.98%)
Streaming Delayed Price Updated: 3:03 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup ↗
BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing... 
Via Chartmill
News headline image
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
From Helix Acquisition Corp. II
Via GlobeNewswire
News headline image
BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat ↗
BridgeBio Pharma reports mixed Q2 2025 results with revenue beating estimates but EPS missing, causing an 11% stock drop. Strong prescription growth contrasts with profitability concerns. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: BridgeBio Pharma's Earnings Forecast ↗
 
Via Benzinga
News headline image
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Is Pfizer Stock a Yield Trap? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis ↗
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
The Smart Money Is Buying These 10 Stocks ↗
 
Via Benzinga
News headline image
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
Via Benzinga
Topics World Trade
News headline image
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations ↗
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
News headline image
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.